Astrazeneca, first mix of antibodies prevents covid

It’s called pre-exposure prophylaxis. It is a well-known approach, for example, for HIV, an infection for which there is now widespread talk of ‘Prep’, which consists in the assumption by high-risk subjects of a pharmacological treatment in a preventive key, to avoid the infection. AstraZeneca has investigated this same approach for the Sars-CoV-2 coronavirus. And today it announces “positive results” for the phase III study on the “first combination of two long-acting antibodies (Laab) to prevent Covid-19”. In this pre-exposure prophylaxis study, dubbed ‘Provent’, “AZD7442 reduced the risk of developing symptomatic Covid-19 by 77%, compared to placebo.”